Systemic Lupus Erythematosus (SLE) Clinical Trials

• Males or females ≥ 50 years of age at time of consent

• ≥ 4 of the 1997 ACR13 or the 2012 SLICC/ACR criteria for SLE (14, 15)

• Clinically stable SLE

• Stable dose of one or more of the following immunosuppressive treatment ≥ 4 weeks

• Corticosteroid use: ≥ 5mg/day of prednisolone equivalent

• Antimalarials (≤ 400 mg/day)

• Azathioprine (≤ 3 mg/kg/day)

• Mycophenolate mofetil (≤ 3 mg/day)

• Tacrolimus (≤ 5mg/day)

• Methotrexate (≤ 20mg/week)

• Cyclosphosphamide (≤ 1mg/BSA/month)

• Must be eligible for the indication of adjuvanted herpes zoster subunit vaccine

• Must understand and voluntarily sign an informed consent form including writing consent for data protection